Oncogenic Kras initiates leukemia in hematopoietic stem cells.
How oncogenes modulate the self-renewal properties of cancer-initiating cells is incompletely understood. Activating KRAS and NRAS mutations are among the most common oncogenic lesions detected in human cancer, and occur in myeloproliferative disorders (MPDs) and leukemias. We investigated the effec...
Main Authors: | Amit J Sabnis, Laurene S Cheung, Monique Dail, Hio Chung Kang, Marianne Santaguida, Michelle L Hermiston, Emmanuelle Passegué, Kevin Shannon, Benjamin S Braun |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-03-01
|
Series: | PLoS Biology |
Online Access: | http://europepmc.org/articles/PMC2656550?pdf=render |
Similar Items
-
Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells.
by: E Camilla Forsberg, et al.
Published: (2010-01-01) -
Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.
by: Reina E Ito, et al.
Published: (2021-01-01) -
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
by: Emmanuelle Kempf, et al.
Published: (2016-03-01) -
Oncogenic KRAS: Signaling and Drug Resistance
by: Hyeon Jin Kim, et al.
Published: (2021-11-01) -
Differential Effector Engagement by Oncogenic KRAS
by: Tina L. Yuan, et al.
Published: (2018-02-01)